

# Mario Masellis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5384189/publications.pdf>

Version: 2024-02-01

173  
papers

9,622  
citations

81900

39  
h-index

43889

91  
g-index

180  
all docs

180  
docs citations

180  
times ranked

11869  
citing authors

#	ARTICLE	IF	CITATIONS
1	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. <i>Brain</i> , 2023, 146, 321-336.	7.6	30
2	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.8	15
3	Elevated regional cerebral blood flow in adults with 22q11.2 deletion syndrome. <i>World Journal of Biological Psychiatry</i> , 2023, 24, 260-265.	2.6	0
4	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
5	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
6	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
7	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
8	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum $\tau$ NfL and $\tau$ pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
9	Differential Cognitive Decline in Alzheimer's Disease Is Predicted by Changes in Ventricular Size but Moderated by Apolipoprotein E and Pulse Pressure. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 545-560.	2.6	4
10	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
11	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
12	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. <i>Human Brain Mapping</i> , 2022, 43, 2089-2108.	3.6	17
13	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
14	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	2.6	3
15	Data-driven staging of genetic frontotemporal dementia using multi-modal $\tau$ MRI. <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
16	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
17	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
18	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1

#	ARTICLE	IF	CITATIONS
19	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	4.6	4
20	The <sc>CBIâ€R</sc> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
21	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i>-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12
22	Small and Large Magnetic Resonance Imagingâ€“Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	3.9	11
23	Effects of white matter hyperintensities, neuropsychiatric symptoms, and cognition on activities of daily living: Differences between Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12306.	2.4	2
24	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	3
25	Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-19.	2.6	1
26	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
27	Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. <i>Annals of Neurology</i> , 2021, 89, 91-98.	5.3	23
28	Graph theory analysis of the dopamine D2 receptor network in Parkinsonâ€™s disease patients with cognitive decline. <i>Journal of Neuroscience Research</i> , 2021, 99, 947-965.	2.9	6
29	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
30	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
31	Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. <i>Neurobiology of Aging</i> , 2021, 100, 22-31.	3.1	22
32	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
33	Extraâ€“striatal dopamine in Parkinson's disease with rapid eye movement sleep behavior disorder. <i>Journal of Neuroscience Research</i> , 2021, 99, 1177-1187.	2.9	9
34	Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1317-1328.	0.8	79
35	Bilingualism in Parkinsonâ€™s disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021, 43, 199-212.	1.3	3
36	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Feasibility of unattended home sleep apnea testing in a cognitively impaired clinic population. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 435-444.	2.6	5
38	Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond. <i>Cmaj</i> , 2021, 193, E371-E377.	2.0	28
39	Teaching Video NeuroImage: "Weighing in on an Unusual Tremor. <i>Neurology</i> , 2021, 97, e970-e971.	1.1	1
40	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.1	14
41	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
42	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
43	White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 129.	6.2	25
44	The <i>APOE</i> $\epsilon$ 4 variant and hippocampal atrophy in Alzheimer's disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 851-870.	2.8	7
45	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	3.8	14
46	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
47	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	3.1	8
48	A Multimodal Risk Network Predicts Executive Function Trajectories in Non-demented Aging. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 621023.	3.4	2
49	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
50	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
51	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	7.6	7
52	Brain atrophy trajectories predict differential functional performance in Alzheimer's disease: Moderations with apolipoprotein E and sex. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12244.	2.4	3
53	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
54	VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder. <i>Molecular Brain</i> , 2021, 14, 165.	2.6	7

#	ARTICLE	IF	CITATIONS
55	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab. <i>Canadian Geriatrics Journal</i> , 2021, 24, 373-378.	1.2	6
56	Pattern of progression in MAPT-related frontotemporal dementia: Results from the GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
57	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
58	Serum oxylipins indicate subcortical ischemic vascular disease in patients with clinical stroke. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
59	From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: A cluster analysis in the GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
60	Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review. <i>European Journal of Neurology</i> , 2020, 27, 229-234.	3.3	35
61	A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap. <i>Brain</i> , 2020, 143, 1315-1331.	7.6	106
62	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
63	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
64	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
65	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
66	Accumulating and heterogeneous network knockout profiles in amnesic mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e039184.	0.8	0
67	Parkinsonism in <i>C9orf72</i> expansion without coexisting Lewy body pathology; a case report and review of the literature. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 786-789.	3.2	2
68	Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRl) Study and Clinical Trials Over the Past 10 Years. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 747-757.	2.6	9
69	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. <i>Brain</i> , 2020, 143, 1632-1650.	7.6	158
70	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
71	Location, Location: The Clue to Aetiology in Cerebellar Bleeds. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 721-723.	0.5	0
72	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55

#	ARTICLE	IF	CITATIONS
73	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
74	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
75	CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12098.	3.7	5
76	Brain degeneration in Parkinson's disease patients with cognitive decline: a coordinate-based meta-analysis. <i>Brain Imaging and Behavior</i> , 2019, 13, 1021-1034.	2.1	33
77	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.5	56
78	&lt;p&gt;Orthostatic hypotension and dementia incidence: links and implications&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	2.2	17
79	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
80	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 491-498.	0.5	7
81	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in $\alpha$ -synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	1.9	73
82	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
83	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2019, 142, 1108-1120.	7.6	41
84	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	7.6	122
85	<i>APOE</i> $\epsilon$ 4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia. <i>Neurology</i> , 2019, 93, e1807-e1819.	1.1	43
86	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
87	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. <i>NeuroImage</i> , 2019, 188, 282-290.	4.2	16
88	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	3.1	47
89	Cognitive profile of non-demented Parkinson's disease: Meta-analysis of domain and sex-specific deficits. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 32-42.	2.2	26
90	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	1.9	21

#	ARTICLE	IF	CITATIONS
91	Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 851-858.	1.9	37
92	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	17
93	Comment: Unraveling DNA sequence to identify cerebral indicators of dementia risk. <i>Neurology</i> , 2018, 90, 109-109.	1.1	0
94	Association between maternal childhood maltreatment and mother-infant attachment disorganization: Moderation by maternal oxytocin receptor gene and cortisol secretion. <i>Hormones and Behavior</i> , 2018, 102, 23-33.	2.1	19
95	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
96	Age representation in antiepileptic drug trials: A systematic review and meta-analysis. <i>Epilepsy Research</i> , 2018, 142, 9-15.	1.6	5
97	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 131-140.	3.4	41
98	Social inappropriateness in neurodegenerative disorders. <i>International Psychogeriatrics</i> , 2018, 30, 197-207.	1.0	66
99	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 191-196.	3.1	151
100	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 245.e9-245.e12.	3.1	40
101	Enhancement of automated blood flow estimates (ENABLE) from arterial spin-labeled MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 647-655.	3.4	30
102	Dopamine receptor D2 (DRD2), dopamine transporter solute carrier family C6, member 4 (SLC6A3), and catechol-O-methyltransferase (COMT) genes as moderators of the relation between maternal history of maltreatment and infant emotion regulation. <i>Development and Psychopathology</i> , 2018, 30, 581-592.	2.3	8
103	Prevalence of amyloid- $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
104	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	12.8	263
105	Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. <i>PLoS Medicine</i> , 2018, 15, e1002647.	8.4	42
106	Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 89.	6.2	11
107	<i>APOE</i> $\epsilon$ 4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2018, 14, 1137-1147.	0.8	39
108	Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. <i>Nature Communications</i> , 2018, 9, 2336.	12.8	618

#	ARTICLE	IF	CITATIONS
109	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 46.	6.2	34
110	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1-16.	2.6	28
111	Heritability estimates of cortical anatomy: The influence and reliability of different estimation strategies. <i>NeuroImage</i> , 2018, 178, 78-91.	4.2	18
112	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.1	35
113	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 20, 222-227.	2.7	5
114	Computer-Based Driving in Dementia Decision Tool With Mail Support: Cluster Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e194.	4.3	6
115	Small vessel disease is linked to disrupted structural network covariance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 749-760.	0.8	30
116	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.	3.9	88
117	Development of cognitive screening test for the severely hearing impaired: Hearing-impaired <sc>M</sc><sc>CA</sc>. <i>Laryngoscope</i> , 2017, 127, S4-S11.	2.0	85
118	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2017, 140, 1784-1791.	7.6	55
119	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
120	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. <i>NeuroImage: Clinical</i> , 2017, 15, 171-180.	2.7	63
121	Collagenosis of the Deep Medullary Veins: An Underrecognized Pathologic Correlate of White Matter Hyperintensities and Periventricular Infarction?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 299-312.	1.7	108
122	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	8.0	177
123	The spatial coefficient of variation in arterial spin labeling cerebral blood flow images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3184-3192.	4.3	76
124	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017, 32, 510-525.	3.9	92
125	Development of a decision-making tool for reporting drivers with mild dementia and mild cognitive impairment to transportation administrators. <i>International Psychogeriatrics</i> , 2017, 29, 1551-1563.	1.0	13
126	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 196-202.	0.5	72



#	ARTICLE	IF	CITATIONS
127	Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1546-1546.	3.9	1
128	Sex differences in the prevalence of genetic mutations in FTD and ALS. <i>Neurology</i> , 2017, 89, 1633-1642.	1.1	47
129	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	5.3	133
130	Maternal DRD2, SLC6A3, and OXTR genotypes as potential moderators of the relation between maternal history of care and maternal cortisol secretion in the context of mother-infant separation. <i>Biological Psychology</i> , 2017, 129, 154-164.	2.2	4
131	Lack of Frank Agrammatism in the Nonfluent Agrammatic Variant of Primary Progressive Aphasia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 6, 407-423.	1.3	12
132	Disinhibition in Alzheimer's Disease is Associated with Reduced Right Frontal Pole Cortical Thickness. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1161-1170.	2.6	20
133	[P4418]: SEX DIFFERENCES IN THE PREVALENCE OF GENETIC MUTATIONS IN FTD AND ALS: A META-ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1491.	0.8	0
134	Peripheral lipid oxidative stress markers are related to vascular risk factors and subcortical small vessel disease. <i>Neurobiology of Aging</i> , 2017, 59, 91-97.	3.1	28
135	Characterizing familial corticobasal syndrome due to Alzheimer's disease pathology and PSEN1 mutations. <i>Alzheimer's and Dementia</i> , 2017, 13, 520-530.		14
136	[P1397]: A PROSPECTIVE OBSERVATIONAL STUDY INVESTIGATING CLINICAL RESPONSE TO CHOLINESTERASE INHIBITORS AND ASSOCIATION WITH CEREBRAL PERFUSION. <i>Alzheimer's and Dementia</i> , 2017, 13, P422.	0.8	0
137	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721.	2.6	54
138	Heritability of hippocampal subfield volumes using a twin and non-twin siblings design. <i>Human Brain Mapping</i> , 2017, 38, 4337-4352.	3.6	27
139	Infant Emotion Regulation Strategy Moderates Relations between Self-Reported Maternal Depressive Symptoms and Infant HPA Activity. <i>Infant and Child Development</i> , 2016, 25, 64-83.	1.5	4
140	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	10.2	100
141	P4169: Cognitive Performance and Functional Connectivity are Modulated by Striatal Dopaminergic Deficit in Adults With Parkinson's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P1082.	0.8	1
142	“Under pressure”: is there a link between orthostatic hypotension and cognitive impairment in ±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	1.9	75
143	P2-190: Diagnostic Disagreement among Major Consensus Criteria for Alzheimer's Disease when Compared to the Nincds-Adrd. <i>Alzheimer's and Dementia</i> , 2016, 12, P691-P692.		0
144	P2260: WHITE MATTER HYPERINTENSITIES AND VERBAL MEMORY: AN INDIRECT RELATIONSHIP MEDIATED BY TEMPORAL LOBE ATROPHY. <i>Alzheimer's and Dementia</i> , 2016, 12, P726.	0.8	0

#	ARTICLE	IF	CITATIONS
145	P1-025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). <i>Alzheimer's and Dementia</i> , 2016, 12, P409.	0.8	0
146	P2-235: Apolipoprotein E E4 Allele and Hippocampal Volumetrics in Alzheimer's Disease: A Systematic Review of Cross-sectional and Longitudinal Studies. <i>Alzheimer's and Dementia</i> , 2016, 12, P713.	0.8	2
147	P2-376: A Driving in Dementia Decision Tool: Preliminary Analysis. <i>Alzheimer's and Dementia</i> , 2016, 12, P789.	0.8	0
148	P2-390: Developing a Dementia Care Pathway in Acute Care Hospitals: A Review of the Literature. , 2016, 12, P794-P795.		0
149	P3-244: Elevated Physiological Fluctuations in White Matter is Related to Disease Severity in Patients with Parkinson's Disease. , 2016, 12, P920-P922.		0
150	P3-254: Perivascular Distribution and Variable Progression of Focal White Matter Hyperintensities in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P926.	0.8	0
151	The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. <i>Npj Genomic Medicine</i> , 2016, 1, 16032.	3.8	26
152	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
153	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	3.7	207
154	MATERNAL SELF-REPORTED DEPRESSIVE SYMPTOMS AND MATERNAL CORTISOL LEVELS INTERACT TO PREDICT INFANT CORTISOL LEVELS. <i>Infant Mental Health Journal</i> , 2016, 37, 125-139.	1.8	26
155	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	2.2	35
156	Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 957-965.	3.8	18
157	Physiological fluctuations in white matter are increased in Alzheimer's disease and correlate with neuroimaging and cognitive biomarkers. <i>Neurobiology of Aging</i> , 2016, 37, 12-18.	3.1	60
158	White matter hyperintensity burden in elderly cohort studies: The Sunnybrook Dementia Study, Alzheimer's Disease Neuroimaging Initiative, and Three-City Study. <i>Alzheimer's and Dementia</i> , 2016, 12, 203-210.	0.8	37
159	IC-P-054: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P42-P42.		0
160	Summary cortisol reactivity indicators: Interrelations and meaning. <i>Neurobiology of Stress</i> , 2015, 2, 34-43.	4.0	110
161	O2-01-01: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P171-P171.		0
162	DRD2 and SLC6A3 moderate impact of maternal depressive symptoms on infant cortisol. <i>Psychoneuroendocrinology</i> , 2015, 62, 243-251.	2.7	16

#	ARTICLE	IF	CITATIONS
163	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. <i>Lancet Neurology</i> , 2015, 14, 253-262.	10.2	432
164	Physician Sex Is a Predictor of Reporting Drivers with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 201-203.	2.6	4
165	Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 71.	6.2	14
166	Developing Physician Consensus on the Reporting of Patients with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities in a Region with Mandatory Reporting Legislation. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1530-1543.	1.2	20
167	P4-095: COMPARISON OF FOUR NEW CONSENSUS CRITERIA AGAINST THE 1984 NINCDS-ARDRA CRITERIA FOR ALZHEIMER'S DISEASE. , 2014, 10, P819-P819.		0
168	P4-180: DESIGN OF THE SARTAN-AD TRIAL. , 2014, 10, P854-P855.		0
169	Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 1.	6.2	286
170	Early-onset dementias: diagnostic and etiological considerations. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S7.	6.2	47
171	Criterion and Convergent Validity of the Montreal Cognitive Assessment with Screening and Standardized Neuropsychological Testing. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 2181-2185.	2.6	99
172	Editorial (Taking the Kidney Personally: The Quest for Novel Antigens of Idiopathic Membranous) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Personalized Medicine</i> , 2013, 11, 5-7.	0.2	0
173	Targeted copy number variant identification across the neurodegenerative disease spectrum. <i>Molecular Genetics &amp; Genomic Medicine</i> , 0, , .	1.2	3